News

The Kurma Biofund II fund is led by Paris-based venture capital firm Kurma Life Science Partners (KLS) and is supported by other investors namely, CDC Entreprises, Idinvest Partners

As per the plan, the project could result in elimination of up to 55 jobs to reduce costs and align more than 30 affiliates in 10 strong business

The research facility includes 30-bed, Phase 1 unit and multiple outpatient clinical examination rooms. As part of the company’s Research Clinics Division, the new facility is also used

The siRNA molecules will be produced in combination with Invivofectamine Rx to create a new platform intended to address human diseases with unmet medical need in China. Ribo

The first alpha particle-emitting radioactive therapeutic agent, Xofigo has been approved by the US Food and Drug Administration (FDA) to treat castration-resistant prostate cancer (CRPC), symptomatic bone metastases

Introduced by A*Star’s ICES, the new program offers a platform for pharma and specialty chemicals industry to deal with challenges, including costs, regulatory compliance and responsiveness in production

Conducted in the US at the University of California San Francisco, the University of Washington and the John Wayne Cancer Institute, the single-arm, open-label study will assess the

The main focus of this collaboration will be to recognize alternative therapeutic indications of marketed compounds for neglected and orphan diseases. In order to deal with the drug

The company has submitted a new drug application for the vaccine to the Ministry of Health, Labour and Welfare in Japan. In August 2011, the Ministry of Health,